Hologic (NASDAQ:HOLX) Given New $95.00 Price Target at Raymond James

Hologic (NASDAQ:HOLX) had its target price lifted by Raymond James from $93.00 to $95.00 in a research report released on Tuesday morning, Benzinga reports. They currently have an outperform rating on the medical equipment provider’s stock.

A number of other analysts have also recently issued reports on the stock. Leerink Partners reduced their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Finally, Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.25.

Hologic Price Performance

NASDAQ HOLX opened at $78.80 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The business’s fifty day moving average is $81.06 and its 200 day moving average is $78.08. The company has a market capitalization of $18.30 billion, a PE ratio of 26.80, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98. Hologic has a fifty-two week low of $66.93 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.89 EPS. Sell-side analysts predict that Hologic will post 4.09 earnings per share for the current year.

Hedge Funds Weigh In On Hologic

A number of institutional investors and hedge funds have recently made changes to their positions in HOLX. Norden Group LLC lifted its holdings in shares of Hologic by 44.0% in the 1st quarter. Norden Group LLC now owns 5,480 shares of the medical equipment provider’s stock valued at $427,000 after acquiring an additional 1,675 shares during the last quarter. Fidelis Capital Partners LLC purchased a new stake in Hologic during the first quarter valued at approximately $63,000. Daiwa Securities Group Inc. lifted its stake in shares of Hologic by 0.8% in the 1st quarter. Daiwa Securities Group Inc. now owns 36,160 shares of the medical equipment provider’s stock valued at $2,819,000 after purchasing an additional 270 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Hologic by 22.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 40,286 shares of the medical equipment provider’s stock worth $3,141,000 after purchasing an additional 7,432 shares during the period. Finally, Central Pacific Bank Trust Division purchased a new stake in Hologic during the 1st quarter valued at $77,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.